{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:31:43Z","timestamp":1767850303418,"version":"3.49.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["AZ 1070-13"],"award-info":[{"award-number":["AZ 1070-13"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pools of overlapping synthetic peptides are routinely used for ex vivo monitoring of antigen-specific T-cell responses. However, it is rather unlikely that these peptides match those resulting from naturally processed antigens. T-activated proteins have been described as immunogenic and more natural stimulants, since they have to pass through antigen processing and comprise activation of all clinically relevant effector cell populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed comparative analysis of numbers and cytokine expression pattern of CD4 and CD8 T cells after stimulation with recombinant, urea-formulated T-activated EBV-BZLF1, -EBNA3A, and HCMV-IE1, and -pp65 proteins or corresponding overlapping peptide pools. Freshly isolated and cryopreserved PBMC of 30 EBV- and 19 HCMV-seropositive and seven EBV- and HCMV-seronegative subjects were stimulated ex vivo and analysed for IFN-\u03b3, TNF and IL-2 production by flow cytometry-based intracellular cytokine staining.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>T-activated proteins showed a high specificity of 100% (EBV-BZLF1, HCMV-IE1, and -pp65) and 86% (EBV-EBNA3A), and a high T-cell stimulatory capacity of 73\u201395% and 67\u201395% using freshly isolated and cryopreserved PBMC, respectively. The overall CD4 T-cell response rates in both cohorts were comparable after stimulation with either T-activated protein or peptide pools with the exception of lower numbers of CD8 T cells detected after stimulation with T-activated EBV-EBNA3A- (<jats:italic>p<\/jats:italic>\u2009=\u20090.038) and HCMV-pp65- (<jats:italic>p<\/jats:italic>\u2009=\u20090.0006). Overall, the number of detectable antigen-specific T cells varied strongly between individuals. Cytokine expression patterns in response to T-activated protein and peptide pool-based stimulation were similar for CD4, but significantly different for CD8 T-cell responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>EBV and HCMV-derived T-activated proteins represent innovative, highly specific recall antigens suitable for use in immunological endpoint assays to evaluate success or failure in immunotherapy clinical trials (e.g. to assess the risk of EBV and\/or HCMV reactivation after allogenic hematopoietic stem cell transplantation). T-activated proteins could be of particular importance, if an impaired antigen processing (e.g. in a post-transplant setting) must be taken into account.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-020-02385-x","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T12:02:58Z","timestamp":1592395378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of T-activated proteins as recall antigens to monitor Epstein\u2013Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-6547","authenticated-orcid":false,"given":"Nina","family":"K\u00f6rber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Behrends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"issue":"Suppl 3","key":"2385_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.12002","volume":"13","author":"JA Fishman","year":"2013","unstructured":"Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13(Suppl 3):1\u20138 (quiz 8).","journal-title":"Am J Transplant"},{"issue":"5","key":"2385_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/molecules24050997","volume":"24","author":"G Andrei","year":"2019","unstructured":"Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein-Barr virus. Molecules. 2019;24(5):997.","journal-title":"Molecules"},{"issue":"9","key":"2385_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1086\/508173","volume":"43","author":"SA Staras","year":"2006","unstructured":"Staras SA, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988\u20131994. Clin Infect Dis. 2006;43(9):1143\u201351.","journal-title":"Clin Infect Dis"},{"key":"2385_CR4","first-page":"1898","volume-title":"Fields virology","author":"RM Longnecker","year":"2007","unstructured":"Longnecker RM, Kieff ED, Cohen JI. Epstein\u2013Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2007. p. 1898\u2013954."},{"issue":"1","key":"2385_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1073\/pnas.59.1.94","volume":"59","author":"G Henle","year":"1968","unstructured":"Henle G, Henle W, Diehl V. Relation of Burkitt\u2019s tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA. 1968;59(1):94\u2013101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2385_CR6","doi-asserted-by":"publisher","first-page":"911.e1\u20138","DOI":"10.1016\/j.amjmed.2006.12.011","volume":"120","author":"C Hurt","year":"2007","unstructured":"Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120(10):911.e1\u20138.","journal-title":"Am J Med"},{"key":"2385_CR7","doi-asserted-by":"publisher","first-page":"931952","DOI":"10.1155\/2012\/931952","volume":"2012","author":"D Martorelli","year":"2012","unstructured":"Martorelli D, et al. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein\u2013Barr-virus-driven disorders. Clin Dev Immunol. 2012;2012:931952.","journal-title":"Clin Dev Immunol"},{"key":"2385_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-019-0591-5","author":"HH Balfour Jr","year":"2019","unstructured":"Balfour HH Jr, Schmeling DO, Grimm-Geris JM. The promise of a prophylactic Epstein\u2013Barr virus vaccine. Pediatr Res. 2019. https:\/\/doi.org\/10.1038\/s41390-019-0591-5.","journal-title":"Pediatr Res"},{"issue":"4","key":"2385_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","volume":"70","author":"SL Glaser","year":"1997","unstructured":"Glaser SL, et al. Epstein\u2013Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375\u201382.","journal-title":"Int J Cancer"},{"issue":"12","key":"2385_CR10","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1073\/pnas.71.12.4737","volume":"71","author":"G Klein","year":"1974","unstructured":"Klein G, et al. Direct evidence for the presence of Epstein\u2013Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci USA. 1974;71(12):4737\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2385_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.1711650105","volume":"165","author":"G Niedobitek","year":"1991","unstructured":"Niedobitek G, et al. Epstein\u2013Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol. 1991;165(1):17\u201324.","journal-title":"J Pathol"},{"issue":"11","key":"2385_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1212\/01.wnl.0000247665.94088.8d","volume":"67","author":"D Pohl","year":"2006","unstructured":"Pohl D, et al. High seroprevalence of Epstein\u2013Barr virus in children with multiple sclerosis. Neurology. 2006;67(11):2063\u20135.","journal-title":"Neurology"},{"issue":"4","key":"2385_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","volume":"96","author":"CN Kotton","year":"2013","unstructured":"Kotton CN, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333\u201360.","journal-title":"Transplantation"},{"issue":"6","key":"2385_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/cis993","volume":"56","author":"O Manuel","year":"2013","unstructured":"Manuel O, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817\u201324.","journal-title":"Clin Infect Dis"},{"key":"2385_CR15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229252","author":"E Wagner-Drouet","year":"2019","unstructured":"Wagner-Drouet E, et al. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.229252.","journal-title":"Haematologica"},{"issue":"1\u20132","key":"2385_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-1759(01)00416-1","volume":"255","author":"HT Maecker","year":"2001","unstructured":"Maecker HT, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255(1\u20132):27\u201340.","journal-title":"J Immunol Methods"},{"issue":"2","key":"2385_CR17","doi-asserted-by":"publisher","first-page":"e0147812","DOI":"10.1371\/journal.pone.0147812","volume":"11","author":"A Fiore-Gartland","year":"2016","unstructured":"Fiore-Gartland A, et al. Pooled-peptide epitope mapping strategies are efficient and highly sensitive: an evaluation of methods for identifying human T cell epitope specificities in large-scale HIV vaccine efficacy trials. PLoS ONE. 2016;11(2):e0147812.","journal-title":"PLoS ONE"},{"issue":"2","key":"2385_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/intimm\/dxh197","volume":"17","author":"KL Smith","year":"2005","unstructured":"Smith KL, et al. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol. 2005;17(2):167\u201376.","journal-title":"Int Immunol"},{"issue":"31","key":"2385_CR19","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1016\/j.vaccine.2014.04.040","volume":"32","author":"EE Giorgi","year":"2014","unstructured":"Giorgi EE, et al. Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine. 2014;32(31):3995\u20134000.","journal-title":"Vaccine"},{"issue":"1","key":"2385_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QAI.0b013e3180377b5b","volume":"45","author":"S Dubey","year":"2007","unstructured":"Dubey S, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007;45(1):20\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1\u20132","key":"2385_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-1759(02)00541-0","volume":"275","author":"R Draenert","year":"2003","unstructured":"Draenert R, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods. 2003;275(1\u20132):19\u201329.","journal-title":"J Immunol Methods"},{"key":"2385_CR22","doi-asserted-by":"publisher","first-page":"25852","DOI":"10.1038\/srep25852","volume":"6","author":"G Spielmann","year":"2016","unstructured":"Spielmann G, et al. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy. Sci Rep. 2016;6:25852.","journal-title":"Sci Rep"},{"issue":"11","key":"2385_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00262-012-1251-3","volume":"61","author":"SK Singh","year":"2012","unstructured":"Singh SK, et al. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother. 2012;61(11):1953\u201363.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2385_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","volume":"32","author":"M Andreatta","year":"2016","unstructured":"Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32(4):511\u20137.","journal-title":"Bioinformatics"},{"key":"2385_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","volume":"8","author":"M Wieczorek","year":"2017","unstructured":"Wieczorek M, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8:292.","journal-title":"Front Immunol"},{"issue":"2","key":"2385_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1086\/367702","volume":"187","author":"ND Russell","year":"2003","unstructured":"Russell ND, et al. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003;187(2):226\u201342.","journal-title":"J Infect Dis"},{"issue":"11","key":"2385_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cyto.a.20646","volume":"73","author":"ML Precopio","year":"2008","unstructured":"Precopio ML, et al. Optimizing peptide matrices for identifying T-cell antigens. Cytom A. 2008;73(11):1071\u20138.","journal-title":"Cytom A"},{"issue":"1","key":"2385_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri1256","volume":"4","author":"H Hackstein","year":"2004","unstructured":"Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004;4(1):24\u201334.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2385_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007890-200301150-00025","volume":"75","author":"P Monti","year":"2003","unstructured":"Monti P, et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation. 2003;75(1):137\u201345.","journal-title":"Transplantation"},{"issue":"7","key":"2385_CR30","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO;2-N","volume":"30","author":"AM Woltman","year":"2000","unstructured":"Woltman AM, et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol. 2000;30(7):1807\u201312.","journal-title":"Eur J Immunol"},{"issue":"3","key":"2385_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1365-2567.2003.01585.x","volume":"108","author":"K Tajima","year":"2003","unstructured":"Tajima K, et al. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology. 2003;108(3):321\u20138.","journal-title":"Immunology"},{"issue":"4","key":"2385_CR32","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/TP.0b013e318224f263","volume":"92","author":"C Solano","year":"2011","unstructured":"Solano C, et al. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation. 2011;92(4):e17\u201320.","journal-title":"Transplantation"},{"issue":"11","key":"2385_CR33","doi-asserted-by":"publisher","first-page":"e1000198","DOI":"10.1371\/journal.ppat.1000198","volume":"4","author":"S Barabas","year":"2008","unstructured":"Barabas S, et al. Urea-mediated cross-presentation of soluble Epstein\u2013Barr virus BZLF1 protein. PLoS Pathog. 2008;4(11):e1000198.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2385_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12865-017-0195-y","volume":"18","author":"S Barabas","year":"2017","unstructured":"Barabas S, et al. An optimized IFN-gamma ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 2017;18(1):14.","journal-title":"BMC Immunol"},{"issue":"1","key":"2385_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12865-017-0194-z","volume":"18","author":"B Banas","year":"2017","unstructured":"Banas B, et al. Validation of T-Track(R) CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017;18(1):15.","journal-title":"BMC Immunol"},{"issue":"4","key":"2385_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/tri.13110","volume":"31","author":"B Banas","year":"2018","unstructured":"Banas B, et al. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. 2018;31(4):436\u201350.","journal-title":"Transpl Int"},{"issue":"2","key":"2385_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/eji.200737768","volume":"38","author":"MG Duvall","year":"2008","unstructured":"Duvall MG, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008;38(2):350\u201363.","journal-title":"Eur J Immunol"},{"issue":"12","key":"2385_CR38","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","volume":"107","author":"MR Betts","year":"2006","unstructured":"Betts MR, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781\u20139.","journal-title":"Blood"},{"issue":"4","key":"2385_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2385_CR40","doi-asserted-by":"publisher","first-page":"e74744","DOI":"10.1371\/journal.pone.0074744","volume":"8","author":"SK Tey","year":"2013","unstructured":"Tey SK, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS ONE. 2013;8(10):e74744.","journal-title":"PLoS ONE"},{"issue":"6","key":"2385_CR41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00430-019-00629-2","volume":"208","author":"A Chiereghin","year":"2019","unstructured":"Chiereghin A, et al. Clinical utility of measuring Epstein\u2013Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study. Med Microbiol Immunol. 2019;208(6):825\u201334.","journal-title":"Med Microbiol Immunol"},{"issue":"1","key":"2385_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-010-0940-z","volume":"60","author":"CM Britten","year":"2011","unstructured":"Britten CM, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2011;60(1):15\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2385_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","volume":"31","author":"S Janetzki","year":"2009","unstructured":"Janetzki S, et al. \u201cMIATA\u201d-minimal information about T cell assays. Immunity. 2009;31(4):527\u20138.","journal-title":"Immunity"},{"issue":"1","key":"2385_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12967-016-0932-7","volume":"14","author":"N K\u00f6rber","year":"2016","unstructured":"K\u00f6rber N, et al. Validation of an IFNgamma\/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med. 2016;14(1):175.","journal-title":"J Transl Med"},{"issue":"2","key":"2385_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom A. 2011;79(2):167\u201374.","journal-title":"Cytom A"},{"issue":"7","key":"2385_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/nprot.2015.068","volume":"10","author":"S Janetzki","year":"2015","unstructured":"Janetzki S, et al. Guidelines for the automated evaluation of Elispot assays. Nat Protoc. 2015;10(7):1098\u2013115.","journal-title":"Nat Protoc"},{"issue":"10","key":"2385_CR47","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie Z, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010;59(10):1489\u2013501.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2385_CR48","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.transproceed.2013.07.033","volume":"45","author":"M Ritta","year":"2013","unstructured":"Ritta M, et al. Evaluation of Epstein\u2013Barr virus-specific immunologic response in solid organ transplant recipients with an enzyme-linked ImmunoSpot assay. Transplant Proc. 2013;45(7):2754\u20137.","journal-title":"Transplant Proc"},{"key":"2385_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jim.2014.05.011","volume":"408","author":"S Tischer","year":"2014","unstructured":"Tischer S, et al. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein\u2013Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. J Immunol Methods. 2014;408:101\u201313.","journal-title":"J Immunol Methods"},{"issue":"3","key":"2385_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/vim.2004.17.445","volume":"17","author":"E Sinclair","year":"2004","unstructured":"Sinclair E, et al. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol. 2004;17(3):445\u201354.","journal-title":"Viral Immunol"},{"issue":"6","key":"2385_CR51","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/ajt.13684","volume":"16","author":"M Sester","year":"2016","unstructured":"Sester M, et al. The \u201cABC\u201d of virus-specific T cell immunity in solid organ transplantation. Am J Transplant. 2016;16(6):1697\u2013706.","journal-title":"Am J Transplant"},{"issue":"2","key":"2385_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0161-5890(99)00023-1","volume":"36","author":"G Eberl","year":"1999","unstructured":"Eberl G, et al. Extracellular processing and presentation of a 69-mer synthetic polypetide to MHC class I-restricted T cells. Mol Immunol. 1999;36(2):103\u201312.","journal-title":"Mol Immunol"},{"key":"2385_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","volume":"31","author":"JS Blum","year":"2013","unstructured":"Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443\u201373.","journal-title":"Annu Rev Immunol"},{"key":"2385_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fimmu.2019.00655","volume":"10","author":"PV Lehmann","year":"2019","unstructured":"Lehmann PV, et al. Comprehensive evaluation of the expressed CD8+ T cell epitope space using high-throughput epitope mapping. Front Immunol. 2019;10:655.","journal-title":"Front Immunol"},{"key":"2385_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1745-7580-4-6","volume":"4","author":"C O\u2019Brien","year":"2008","unstructured":"O\u2019Brien C, Flower DR, Feighery C. Peptide length significantly influences in vitro affinity for MHC class II molecules. Immunome Res. 2008;4:6.","journal-title":"Immunome Res"},{"issue":"5","key":"2385_CR56","doi-asserted-by":"publisher","first-page":"e0197407","DOI":"10.1371\/journal.pone.0197407","volume":"13","author":"HS Schultz","year":"2018","unstructured":"Schultz HS, et al. The effect of acylation with fatty acids and other modifications on HLA class II: peptide binding and T cell stimulation for three model peptides. PLoS ONE. 2018;13(5):e0197407.","journal-title":"PLoS ONE"},{"issue":"5","key":"2385_CR57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/511307","volume":"195","author":"C La Rosa","year":"2007","unstructured":"La Rosa C, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis. 2007;195(5):633\u201344.","journal-title":"J Infect Dis"},{"issue":"8","key":"2385_CR58","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1073\/pnas.1815239116","volume":"116","author":"NP Croft","year":"2019","unstructured":"Croft NP, et al. Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci USA. 2019;116(8):3112\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2385_CR59","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4049\/jimmunol.174.2.1037","volume":"174","author":"A Harari","year":"2005","unstructured":"Harari A, et al. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174(2):1037\u201345.","journal-title":"J Immunol"},{"issue":"6","key":"2385_CR60","doi-asserted-by":"publisher","first-page":"e0128714","DOI":"10.1371\/journal.pone.0128714","volume":"10","author":"A Boyd","year":"2015","unstructured":"Boyd A, et al. Pathogen-specific T Cell polyfunctionality is a correlate of T cell efficacy and immune protection. PLoS ONE. 2015;10(6):e0128714.","journal-title":"PLoS ONE"},{"issue":"9","key":"2385_CR61","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/00007890-200105150-00018","volume":"71","author":"M Sester","year":"2001","unstructured":"Sester M, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001;71(9):1287\u201394.","journal-title":"Transplantation"},{"issue":"10","key":"2385_CR62","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/1078-0432.CCR-10-2234","volume":"17","author":"LH Butterfield","year":"2011","unstructured":"Butterfield LH, et al. Recommendations from the iSBTc-SITC\/FDA\/NCI workshop on immunotherapy biomarkers. Clin Cancer Res. 2011;17(10):3064\u201376.","journal-title":"Clin Cancer Res"},{"key":"2385_CR63","unstructured":"FDA. Guidance for industry, bioanalytical method validation. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf. Accessed 14 July 2014."},{"issue":"2","key":"2385_CR64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4049\/jimmunol.168.2.909","volume":"168","author":"B Savoldo","year":"2002","unstructured":"Savoldo B, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002;168(2):909\u201318.","journal-title":"J Immunol"},{"issue":"6","key":"2385_CR65","doi-asserted-by":"publisher","first-page":"e01841-17","DOI":"10.1128\/mBio.01841-17","volume":"8","author":"N Aslan","year":"2017","unstructured":"Aslan N, et al. Severity of acute infectious mononucleosis correlates with cross-reactive influenza CD8 T-cell receptor repertoires. MBio. 2017;8(6):e01841-17.","journal-title":"MBio"},{"key":"2385_CR66","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fimmu.2017.01210","volume":"8","author":"DA Antunes","year":"2017","unstructured":"Antunes DA, et al. Interpreting T-cell cross-reactivity through structure: implications for TCR-based cancer immunotherapy. Front Immunol. 2017;8:1210.","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"2385_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0022-1759(03)00202-3","volume":"278","author":"A Costantini","year":"2003","unstructured":"Costantini A, et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods. 2003;278(1\u20132):145\u201355.","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"2385_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jim.2007.07.012","volume":"326","author":"RE Owen","year":"2007","unstructured":"Owen RE, et al. Loss of T cell responses following long-term cryopreservation. J Immunol Methods. 2007;326(1\u20132):93\u2013115.","journal-title":"J Immunol Methods"},{"issue":"8","key":"2385_CR69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1128\/CVI.00342-08","volume":"16","author":"A Weinberg","year":"2009","unstructured":"Weinberg A, et al. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol. 2009;16(8):1176\u201386.","journal-title":"Clin Vaccine Immunol"},{"issue":"1\u20132","key":"2385_CR70","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(03)00226-6","volume":"278","author":"CR Kreher","year":"2003","unstructured":"Kreher CR, et al. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods. 2003;278(1\u20132):79\u201393.","journal-title":"J Immunol Methods"},{"issue":"3","key":"2385_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cyto.a.22813","volume":"89","author":"L Wang","year":"2016","unstructured":"Wang L, et al. Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoring\u2014development of an algorithm. Cytom A. 2016;89(3):246\u201358.","journal-title":"Cytom A"},{"issue":"2","key":"2385_CR72","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/jmv.24639","volume":"89","author":"E Reuschel","year":"2017","unstructured":"Reuschel E, et al. Functional impairment of CMV-reactive cellular immunity during pregnancy. J Med Virol. 2017;89(2):324\u201331.","journal-title":"J Med Virol"},{"key":"2385_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2172-6-17","volume":"6","author":"HT Maecker","year":"2005","unstructured":"Maecker HT, et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol. 2005;6:17.","journal-title":"BMC Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02385-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T23:18:30Z","timestamp":1623885510000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02385-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02385-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"27 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Studies on material of human origin were approved by the ethics committee of the Technical University of Munich, and informed consent was obtained from all donors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}